What is the primary treatment for a patient with hyperparathyroidism, considering factors such as symptoms, disease severity, and presence of comorbid conditions like osteoporosis, kidney stones, or impaired renal function?

Treatment for Hyperparathyroidism

Primary Hyperparathyroidism

Surgery is the only curative treatment for primary hyperparathyroidism, and parathyroidectomy should be performed in patients with hypercalcemia and elevated PTH. 1

Surgical Indications

Parathyroidectomy is indicated for patients meeting any of the following criteria:

• Age younger than 50 years 2
• Serum calcium >1 mg/dL above upper limit of normal 2
• Impaired kidney function (GFR <60 mL/min/1.73 m²) 3
• Osteoporosis on DEXA scan 3
• Kidney stones or nephrocalcinosis 3, 2
• Symptomatic disease including bone pain, fractures, or neuromuscular symptoms 3
• Hypercalciuria 3

Surgical Approach Selection

Minimally invasive parathyroidectomy (MIP) is the preferred approach when preoperative imaging confidently localizes a single parathyroid adenoma, which accounts for 80-85% of primary hyperparathyroidism cases. 1

• MIP offers shorter operating times, faster recovery, and decreased perioperative costs compared to bilateral neck exploration 1, 3
• MIP requires confident preoperative localization and intraoperative PTH monitoring 3
• Bilateral neck exploration (BNE) remains necessary when preoperative imaging is discordant, nonlocalizing, or when multigland disease is suspected 1

Preoperative Imaging

• Preoperative localization imaging is essential for MIP but not required to establish surgical indication 1
• Common modalities include 99Tc-sestamibi scan (highest sensitivity), ultrasound, 4-D parathyroid CT, and MRI 1, 3
• Imaging should never be used to confirm or exclude the diagnosis of primary hyperparathyroidism—diagnosis is biochemical only 1

Medical Management (Non-Surgical Candidates Only)

Cinacalcet is indicated for treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. 4

• Starting dose: 30 mg twice daily, titrated every 2-4 weeks through sequential doses up to 90 mg 3-4 times daily as necessary to normalize serum calcium 4
• Measure serum calcium within 1 week after initiation or dose adjustment 4
• Cinacalcet effectively lowers serum calcium and PTH levels but does not reduce fracture risk 2

Antiresorptive therapy (bisphosphonates) may be used for skeletal protection in patients with increased fracture risk who cannot undergo surgery. 2

Critical Diagnostic Considerations

• Measure serum calcium (corrected for albumin) and intact PTH simultaneously to confirm diagnosis before treatment 3
• Assess vitamin D status before making surgical decisions—vitamin D deficiency can complicate PTH interpretation and cause secondary hyperparathyroidism 5, 3
• Correct vitamin D deficiency without first exacerbating hypercalcemia 5
• PTH assays vary significantly between laboratories; use assay-specific reference values 3

---

Secondary Hyperparathyroidism (CKD Patients on Dialysis)

Initial medical management is the standard approach for secondary hyperparathyroidism in CKD patients on dialysis, with parathyroidectomy reserved for refractory cases. 3

Medical Management Strategy

For CKD G5D patients, target intact PTH levels in the range of approximately 2 to 9 times the upper normal limit for the assay. 6

Initial therapy includes:

• Dietary phosphate restriction 3
• Phosphate binders (suggest restricting dose of calcium-based binders) 6, 3
• Correction of hypocalcemia with calcium supplementation 3
• Vitamin D sterols (calcitriol, paricalcitol, doxercalciferol) with dosage adjusted according to severity 3

For patients requiring PTH-lowering therapy, use calcimimetics, calcitriol, or vitamin D analogs, or a combination of calcimimetics with calcitriol or vitamin D analogs. 6

Cinacalcet for Secondary Hyperparathyroidism

Cinacalcet is indicated for treatment of secondary hyperparathyroidism in adult patients with CKD on dialysis. 4

• Starting dose: 30 mg once daily 4
• Titrate no more frequently than every 2-4 weeks through sequential doses of 30,60,90,120, and 180 mg once daily to target iPTH levels of 150-300 pg/mL 3, 4
• Measure serum calcium and phosphorus within 1 week, and iPTH 1-4 weeks after initiation or dose adjustment 4
• Cinacalcet is NOT indicated for CKD patients not on dialysis due to increased risk of hypocalcemia 4

Monitoring Requirements

• Serum calcium and phosphorus: every 2 weeks for 1 month after initiation or dose increase, then monthly 3
• PTH: monthly for at least 3 months, then every 3 months once target levels achieved 3
• Monitor for hypocalcemia and increased QT interval with cinacalcet 3

Surgical Indications for Secondary Hyperparathyroidism

Parathyroidectomy is indicated for CKD G3a-G5D patients with severe hyperparathyroidism who fail to respond to medical or pharmacological therapy. 6

Specific indications include:

• Persistent serum intact PTH >800 pg/mL associated with hypercalcemia and/or hyperphosphatemia refractory to medical therapy 3
• Refractory and/or symptomatic hypercalcemia 3
• Refractory hyperphosphatemia 3
• Severe intractable pruritus 3
• Serum calcium × phosphorus product persistently exceeding 70-80 mg/dL with progressive extraskeletal calcifications 3
• Calciphylaxis 3

Surgical Options for Refractory Secondary Hyperparathyroidism

• Total parathyroidectomy (TPTX) without autotransplantation has lower recurrence rates (OR = 0.20) and lower reoperation rates (OR = 0.17) compared to TPTX with autotransplantation 3
• TPTX carries higher risk of hypoparathyroidism (OR = 2.97) 3
• Avoid total parathyroidectomy in patients who may subsequently receive kidney transplant, as calcium control becomes problematic 1
• Exclude aluminum-induced bone disease before proceeding to surgery 3

Dialysate Calcium Management

In CKD G5D patients, use a dialysate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L). 6

---

Parathyroid Carcinoma

Cinacalcet is indicated for treatment of hypercalcemia in adult patients with parathyroid carcinoma. 4

• Starting dose: 30 mg twice daily, titrated every 2-4 weeks up to 90 mg 3-4 times daily as necessary to normalize serum calcium 4
• Measure serum calcium within 1 week after initiation or dose adjustment 4
• Monitor approximately every 2 months once maintenance dose established 4

---

Critical Pitfalls to Avoid

• Never use imaging to confirm or exclude the diagnosis of hyperparathyroidism—diagnosis is biochemical 1
• Always correct vitamin D deficiency before surgical decisions, but avoid exacerbating hypercalcemia 5
• Do not use cinacalcet in CKD patients not on dialysis due to hypocalcemia risk 4
• Avoid total parathyroidectomy in potential kidney transplant recipients 1
• Monitor closely for hypocalcemia with cinacalcet—66-75% of dialysis patients develop calcium <8.4 mg/dL 4
• Recognize that severe nausea and vomiting with cinacalcet can lead to dehydration and worsening hypercalcemia 4